多年来扣押分类:一个翻译表
Sabrina Tavella-Burka1, Patrick Hartnett1, Mark Quigg1
1Department of Neurology, University of Virginia, Charlottesville, Virginia, USA.
Epilepsia
|September 16, 2025
概括
国际抗联盟在2025年更新了其发作分类. 本表翻译了新的发作术语,以帮助在临床实践和研究中理解和采用.
科学领域:
- 神经学 神经学
- 发病学 (Epileptology) 是一个专业的学科.
背景情况:
- 国际抗联盟 (ILAE) 在1981年和2017年建立了发作分类.
- 在2025年推出了修订后的分类,包括用户反和理解机制的进步.
研究的目的:
- 为更新的国际抗联盟发作分类提供翻译表.
- 为了促进过渡,并确保在文学,教育和临床实践中一致的术语.
主要方法:
- 1981年,2017年和2025年国际抗联盟的发作分类的综合审查.
- 开发不同分类版本之间的交叉引用表映射术语.
主要成果:
- 2025年分类引入了对扣押类型和机制的修订术语.
- 翻译表提供了先前和当前扣押术语之间的清晰映射.
结论:
- 更新的发作分类旨在提高描述事件的准确性.
- 这种术语翻译表对于在新分类的采用阶段弥合差距至关重要.
相关概念视频
Seizures: Classification
1.4K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.4K
Epilepsy and Seizures: Overview
1.2K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.2K
Antiepileptic Drugs: Potassium Channel Activators
635
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
635
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
Antiepileptic Drugs: Sodium Channel Blockers
1.6K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.6K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
831
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
831


